2-Isopropyl-2,3-dihydro-1H-benzisochinolin | 65448-52-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-Isopropyl-2,3-dihydro-1H-benzisochinolin
• 英文别名: 2-Propan-2-yl-1,3-dihydrobenzo[de]isoquinoline
• CAS: 65448-52-4
• 化学式: C₁₅H₁₇N
• 分子量: 211.307
• InChiKey: XFUCCUIIQPTGPN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-Isopropyl-2,3-dihydro-1H-benzisochinolin 以26%的产率得到
  参考文献：
  名称：

  POTMISCHIL F.; ROEMER D., REV. ROUM. CHIM. , 1977, 22, NO 9-10, 1375-1378

  摘要：

  DOI：

文献信息

• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080279821A1

  公开（公告）日：2008-11-13

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及具有以下结构的化合物I，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰乙型肝炎病毒的生命周期，并且还可用作抗病毒剂。本发明还涉及含有上述化合物的制药组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者施用含有本发明化合物的制药组合物来治疗受试者的HCV感染的方法。
• ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
  申请人：Niu Deqiang

  公开号：US20080317712A1

  公开（公告）日：2008-12-25

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US7482468B2
  申请人：——

  公开号：US7482468B2

  公开（公告）日：2009-01-27